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Sjögren syndrome is a systemic autoimmune disease causing
secretory gland dysfunction. This leads to dryness of the main
mucosal surfaces such as themouth, eyes, nose, pharynx, larynx,
and vagina.1 Sjögren syndrome may be a serious disease, with
excess mortality caused by haematological cancer.2 The cause
of Sjögren syndrome is unknown, but factors postulated to play
a role are both genetic and environmental.1 The disease
overwhelmingly affects middle aged women but may also affect
children, men, and elderly people.When sicca symptoms appear
in a previously healthy person, the syndrome is classified as
primary Sjögren syndrome. Sjögren syndrome associated with
another underlying systemic autoimmune disorder, such as
systemic lupus erythematosus, rheumatoid arthritis, or
scleroderma is known as secondary or, increasingly, associated
Sjögren syndrome.
Sicca symptoms (dry mouth and eyes) are among the most
common oral and ocular complaints seen by general
practitioners, but even so the disease is often underdiagnosed
or misdiagnosed.3 4Although incidence data in primary care are
scarce, preliminary reports suggest it may be around two per
1000 patients per year,5 with an overall prevalence in Europe
of nearly 0.1%.6 7 Patients with Sjögren syndrome require a
health spend double that of the mean for primary care patients
and similar to that for patients with rheumatoid arthritis.8 9
What are the presenting symptoms and
signs?
There are three predominant clinical presentations, which may
occur at onset or later and often overlap.
Sicca syndrome
Xerostomia (subjective feeling of mouth dryness) and
xerophthalmia (subjective feeling of eye dryness) are the key
symptoms in the diagnosis of Sjögren syndrome, occurring in
more than 95% of patients; a positive answer to at least one of
the three questions about ocular or oral symptoms included in
the current classification criteria (box 1) has a positive value of
54-77%, and a negative answer has a negative predictive value
of 94-98%.10 11Other oral symptoms include soreness, adherence
of food to the mucosa, and dysphagia. Reduced salivary volume
interferes with speaking or eating and may facilitate local
infection, tooth decay, and periodontal disease. Oral signs
include a lobulated or depapillated red tongue and angular
cheilitis (fig 1⇓). Xerophthalmia encompasses itching and
grittiness, andmay be associated with soreness, photosensitivity,
ocular fatigue, and reduced visual acuity. Diminished tear
secretion may lead to chronic irritation and destruction of
conjunctival epithelia (keratoconjunctivitis sicca), with greater
susceptibility to ocular infections. Additional sicca symptoms
that often coexist with dry eyes and mouth include hoarseness,
non-productive cough, skin dryness and, in women, dyspareunia.
Nearly 30% of patients may present inflammatory, episodic
swelling of themajor salivary glands (parotid and submandibular
glands).12
General symptoms
Abnormal fatigue may be a reason for consultation; it is reported
by about 70–80% of patients with Sjögren syndrome and is
often related to work disability.13 14Other non-specific symptoms
closely associated with fatigue are sleep disturbances, anxiety,
and depression, with a prevalence of nearly 15%, 20%, and 40%
of patients with primary Sjögren syndrome, respectively.14-16
Chronic pain is often associated with polyarthralgia andmyalgia,
which are reported by more than 50% of patients.1 Careful
assessment is essential, as this set of symptoms is also
characteristic of other conditions (including menopause,
hypothyroidism, neoplasia, primary depression, and, above all,
fibromyalgia). Some patients, especially children and young
adults, may present with low grade, self limiting fever.
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Methods
We searched Medline for English language articles published between 1 January 1986 and 31 August 2011 for studies in adult humans
using the MeSH term “Sjögren’s syndrome.” Duplicate publications, case reports, experimental studies, and uncontrolled series with fewer
than 10 patients were excluded. We also manually searched the reference list of relevant articles retrieved. Study designs were considered
in the following order (listed from highest to lowest evidence quality): controlled trials, prospective cohort studies, case-control studies,
retrospective studies, and case series.
Box 1 2002 American-European classification criteria for Sjögren syndrome11
1. Ocular symptoms—A positive response to at least one of the following questions:
a) Have you had daily, persistent, troublesome dry eyes for more than 3 months?
b) Do you have a recurrent sensation of sand or gravel in the eyes?
c) Do you use tear substitutes more than three times a day?
2. Oral symptoms—A positive response to at least one of the following questions:
a) Have you had a daily feeling of dry mouth for more than 3 months?
b) Have you had recurrently or persistently swollen salivary glands as an adult?
c) Do you frequently drink liquids to aid in swallowing dry food?
3. Ocular signs—Objective evidence of ocular involvement defined as a positive result for at least one of the following tests:
a) Schirmer’s test for tear function, performed without anaesthesia (positive result ≤5 mm in 5 minutes)
b) Rose Bengal score or other ocular dye score (positive result score ≥4 on the van Bijsterveld scoring system)
4. Histopathology—In minor salivary glands (obtained through normal appearing mucosa) focal lymphocytic sialoadenitis, evaluated by
an expert histopathologist, with a focus score of 1 (defined as the number of lymphocytic foci (which are adjacent to normal appearing
mucous acini and contain >50 lymphocytes) per 4 mm2 of glandular tissue)
5. Salivary gland involvement—Objective evidence of salivary gland involvement defined by a positive result for at least one of the
following tests:
a) Unstimulated whole salivary flow (<1.5 mL in 15 minutes)
b) Parotid sialography showing presence of diffuse sialectasias (punctate, cavitary, or destructive pattern) without evidence of obstruction
in the major ducts
c) Salivary scintigraphy showing delayed uptake, reduced concentration, or delayed excretion of tracer
6. Autoantibodies to Ro/SS-A or La/SS-B antigens, or both
Presence of primary Sjögren syndrome
Patients are classified as having primary Sjögren syndrome when they fulfil ≥4 of the 6 criteria; either criterion 4 (salivary gland pathology)
or 6 (autoantibodies) is mandatory
Exclusion criteria—Past head and neck radiation treatment, hepatitis C infection, AIDS, pre-existing lymphoma, sarcoidosis, graft versus
host disease, use of anticholinergic drugs
Organ specific involvement
Patients may develop several systemic manifestations, either at
presentation or later (box 2).
How can the disease be diagnosed?
Early diagnosis may alleviate symptoms and ensure timely
treatment of symptoms and complications. Definitive diagnosis
of Sjögren syndrome requires the fulfilment of four or more of
the current classification criteria (box 1).11 Fulfilment of at least
four of these criteria (which must include the histopathological
or antibody criteria) has a sensitivity of 93.5% and a specificity
of 94%.
Primary care investigation
Clinical—The diagnostic approach for GPs starts by discarding
other causes of dry eyes (allergic conjunctivitis, blepharitis,
rosacea) and dry mouth, including diabetes, chronic viral
infections, dehydration, irradiation of salivary glands, and,
especially, drugs (box 3).5 The study of impaired saliva and
lacrimal secretions is not routinely available in primary care.
However, two tests—unstimulated salivary flowmeasurement,
and Schirmer’s test—have simple technical requirements readily
available in a GP surgery (graduated tube and a small strip of
filter paper, respectively), but they require time and practice to
be feasible for GPs. For salivary flow measurement, the patient
is instructed to spit saliva into a graduated test tube every
minute; a quantity of <1.5 mL collected over a 15 minute period
indicates impaired saliva secretion. Schirmer’s test consists of
a strip of filter paper placed in the lower conjunctival corneal
sac; lacrimal wetting of <5 mm of the paper after 5 minutes
shows abnormality. Clinical suspicion of Sjögren syndrome
should increase when systemic manifestations (box 2)
accompany the sicca complaints.
Investigations—Routine blood tests have a role: 25% of patients
with Sjögren syndrome have an erythrocyte sedimentation rate
>50 mm in the first hour, while 30% have cytopenias
(normocytic anaemia, lymphopenia, neutropenia, or
thrombocytopenia). These tests are not sufficiently accurate to
make the diagnosis, but they may help point to a systemic cause
of sicca features.17 19 Other tests available in primary care that
will suggest an autoimmune origin of the sicca syndrome include
hypergammaglobulinaemia, rheumatoid factor, and antinuclear
antibodies, which have a low sensitivity (40–69%) but higher
specificity and positive predictive values (>90%).10 20 These
immunological tests may be central in differentiating Sjögren
syndrome from non-autoimmune causes of sicca syndrome.
Specialised investigation
To confirm the diagnosis, refer suspected cases of Sjögren
syndrome to an ophthalmologist and to a specialist in
autoimmune diseases for a specific diagnostic investigation,
since themost common symptoms (sicca and general symptoms)
are non-specific and extremely common inmiddle aged women.
Ocular and oral involvement should be measured objectively.
Complete ophthalmological assessment should include
Schirmer’s test and corneal staining with colorants (rose Bengal,
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Box 2 Major systemic manifestations of Sjögren syndrome (percentages of cases in large case series1 2 12 17 18)
Skin
• Purpura (10–15%) often related to cryoglobulinaemia
• Annular erythema (photosensitive erythematous lesions with indurated borders, see fig 2⇓) (5–10%)
Joints
• Non-erosive symmetrical arthritis (15–30%)
Lungs
• Chronic obstructive lung disease (10%)
• Bronchiectasis (8%)
• Interstitial lung disease (5%)
Cardiovascular
• Raynaud’s phenomenon (18–37%)
• Pericarditis (<5%)
• Symptoms of autonomic dysfunction
Liver
• Primary biliary cirrhosis (3–8%)
• Autoimmune hepatitis (<5%)
• Fetal congenital heart block in babies of mothers with anti-Ro autoantibodies
Pancreas
• Recurrent pancreatitis (<5%)
Nephro-urological
• Renal tubular acidosis (11%)
• Glomerulonephritis (<5%)
• Interstitial cystitis (<5%)
• Recurrent renal colic due to renal stones (<5%)
Peripheral nerves
• Mixed polyneuropathy (5–10%)
• Pure sensory neuronopathy (5%)
• Mononeuritis multiplex (5%)
• Small fibre neuropathy (<5%)*
Central nervous system
• White matter lesions (multiple sclerosis-like disease) (<5%)
• Cranial nerve involvement (V, VIII, and VII) (7%)
• Myelitis (<5%)
Thyroid
• Autoimmune thyroiditis (14–33%)
Haematological
• Autoimmune haemolytic anaemia (<5%)
• Severe thrombocytopenia <10 ×106/L(<5%)
• B cell lymphoma (5–10%)
*Patients with small fibre neuropathy often present with painful burning dysaesthesia of the distal limbs. Because electromyographic
studies may be normal, a skin biopsy often confirms the diagnosis.
fluorescein) (fig 3⇓) for slit lamp examination to detect
conjunctival epithelium destroyed by desiccation. Oral
involvement may be evaluated either by the measurement of
salivary flow or by parotid scintigraphy. Salivary flow
measurement has a sensitivity of 56% and a specificity of 81%
for Sjögren syndrome.11 Parotid scintigraphy has greater
sensitivity (80%) and specificity (86%)10 and evaluates the grade
of involvement of the major salivary glands; severe involvement
(grade IV) at diagnosis is prospectively associated with an
increased risk of lymphoma and death.21
Immunological study must include determination of
autoantibodies to Ro/SS-A and La/SS-B antigens, which are
positive in 50–70% of patients and are the only immunological
parameter included in the current criteria, with a low sensitivity
(33–46%) but a specificity of 100%.10 Other parameters that
should be tested for, or ruled out, are complement levels, serum
monoclonal band, and cryoglobulins (hypocomplementaemia,
monoclonal gammopathy, and mixed cryoglobulinaemia are
associated with increased risk of lymphoma and death).18 19
Finally, minor salivary gland biopsy, although invasive, is highly
specific for the diagnosis of Sjögren syndrome, with a sensitivity
of 82% and a specificity of 86%,11 and is indicated principally
in patients with negative anti-Ro/La antibodies; focal
lymphocytic sialadenitis (aggregates of >50 lymphocytes) is
the characteristic histopathological feature.1
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Box 3 Drugs causing sicca syndrome
• Anticholinergic drugs (atropine, scopolamine)
• Sympathomimetic drugs (ephedrine)
• Benzodiazepines
• Selective serotonin reuptake inhibitors
• Tricyclic antidepressants
• Phenothiazines
• Antihistamines
• Nicotine
• Opioids
• α1 antagonists (terazosin and prazosin)
• α2 agonists (clonidine)
• β blockers (atenolol, propranolol)
• Diuretics
When to refer to a specialist
All suspected cases of Sjögren syndrome should be referred to
specialist care to confirm the diagnosis. However, specific
symptoms suggesting systemic involvement (box 2) may require
referral to the appropriate specialist. Be aware of some
symptoms or analytical abnormalities that may signal possible
systemic complications: these include dyspnoea (interstitial
lung disease), paraesthesia or ataxia (peripheral neuropathy),
focal neurological symptoms (multiple sclerosis-like lesions,
fig 4⇓), recurrent renal colic or raised serum creatinine
(interstitial nephritis or glomerulonephritis), and raised alkaline
phosphatase or bilirubin (primary biliary cirrhosis). Refer
patients with persistent high fever or night sweats, unexplained
weight loss, polyadenopathies, or increased or persistent (>1
month) parotid swelling to a haematologist to rule out
haematological neoplasia.
What are the complications?
Untreated dry mouth can result in dental loss, oral candidiasis,
and periodontal disease, while untreated severe dry eye may
result in corneal ulcers and further perforation. Undiagnosed
involvement of other organs may delay appropriate therapy,
resulting, in some cases, in end stage organ failure (renal failure,
pulmonary fibrosis, progressive neurological disease) and death.
Objective standardised evaluation of the disease burden has
been facilitated by two recently proposed international
indexes.22 23Haematological neoplasia is the main complication
of Sjögren syndrome, with patients with Sjögren syndrome
having a 10–50 times higher risk of lymphoma than healthy
individuals, and the largest case series found that 2–9% of
patients with primary Sjögren syndrome develop
lymphoma.18 19 24 Prospective studies have identified parotid
enlargement, purpura, cryoglobulins, monoclonal band, and
hypocomplementaemia as clinical and immunological risk
factors.
How should patients with Sjögren
syndrome be treated?
Alcohol and smoking should be avoided, and thorough oral
hygiene is essential. Environmental irritants such as smoke,
wind, air conditioning, and low humidity may exacerbate ocular
symptoms. Treatment of dry eyes should start with
preservative-free teardrops and ocular lubricating ointments.
The addition of ocular 0.05% ciclosporin in patients with
refractory severe disease is supported by controlled trials.25 For
dry mouth, mechanical or gustatory stimulation (sugar-free
chewing gum or citric juices) and moisture replacements may
be tried first. Controlled trials support the use of oral muscarinic
agonists (pilocarpine and cevimeline) for patients with residual
salivary gland function.25
Systemic therapy should be tailored to the organ affected and
the severity.25 However, the limited evidence available for the
drugs most often used with Sjögren syndrome makes firm
recommendations difficult. Non-steroidal anti-inflammatory
drugs usually provide relief from minor musculoskeletal
symptoms; if these symptoms become chronic, add
hydroxychloroquine, which has been shown to improve fatigue,
arthralgias, andmyalgias in uncontrolled observational studies.25
According to evidence from some small retrospective studies
and isolated case reports, glucocorticoids or immunosuppressive
agents should not be used in these patients, but only in patients
with potentially severe systemic involvement.25 Evidence from
controlled trials suggests tumour necrosis factor blockers are
not efficacious and that B cell targeted agents (rituximab and
belimumab) may be more promising therapies.26
How to follow up and monitor
Patients with stable disease limited to mucosal surfaces may
require only annual evaluation by their GP or specialist, while
those with extraglandular manifestations should be evaluated
every six months and those with end organ damage every three
months by the specialist in autoimmune diseases.1 Patients
should be routinely asked about cutaneous lesions, night sweats,
and weight loss. Routine physical examination should include
evaluation of the mouth and eyes to exclude local complications
and examination for peripheral lymphadenopathy and
enlargement of parotid and submandibular glands, the liver, and
the spleen. Yearly laboratory tests should include full blood
count, erythrocyte sedimentation rate, and renal and liver
function tests as part of the basic investigation for complications.
Immunological tests are not necessary in routine follow-up with
two exceptions—patients with markers associated with a poor
prognosis (low complement levels, mixed cryoglobulinaemia,
monoclonal gammopathy), and when there is clinical suspicion
of a concomitant systemic autoimmune disease (development
of severe Raynaud’s disease or cutaneous sclerosis suggesting
systemic sclerosis, or erosive arthritis suggesting rheumatoid
arthritis).27 Advise fertile women with anti-Ro/La antibodies
about the risk of fetal congenital heart block, which has a
frequency of <5% and may cause fetal death or the need for a
pacemaker in the newborn.
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Patient’s story
When I was 27, blood tests showed I had an inflamed liver and I was diagnosed with autoimmune hepatitis. Two years later, I started having
sicca symptoms, which led to more tests and a final diagnosis of Sjögren syndrome after five more years of visiting a number of specialists.
In fact, the first symptoms occurred when I was a teenager, but my doctors didn’t know what was wrong. I was very scared and I had many
questions and wondered about my future.
It was difficult at first living with this. Sicca symptoms are present every day, with severe periods that may be related to stress or which can
be completely unexpected. Various external factors—such as air conditioning; working with computers, smart phones, or tablets; bright or
windy weather—repeatedly worsen the symptoms of dry eye, dry mouth, and dry throat, and I often feel quite down. Joint pain and fatigue
are terrible and have a big effect on my daily activities, making it difficult to work overtime or even enjoy dinner with my family and friends.
Most people don’t know about the disease and its consequences, and colleagues, friends, and relatives don’t understand why I’m not OK,
especially when I seem healthy at first sight.
Now, 12 years later, I take it day by day and derive pleasure from the things I enjoy and can do. I follow a diet and exercise plan, and manage
the bad days better than I would have been able to without the knowledge I now have. I think about other people with Sjögren syndrome,
because I don’t want them to go through the same medical labyrinth of waiting, confusion, and fear—so, in 2006, I cofounded the Catalan
Association of Patients with Sjögren Syndrome.
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Figures
Fig 1 Depapillated red tongue and angular cheilitis
Fig 2 Annular erythema associated with Sjögren syndrome (also called Ro associated cutaneous lesions or subacute
lupus-like lesions)
Fig 3 Corneal staining with fluorescein
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e3821 doi: 10.1136/bmj.e3821 (Published 14 June 2012) Page 6 of 7
PRACTICE
Fig 4 Magnetic resonance image of demyelinating central nervous system lesions (multiple sclerosis-like)
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